




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/85, 9/64, C12Q 1/68, A61K 31/70, 48/00 // C12N 5/10	A1	(11) International Publication Number: WO 99/43840 (43) International Publication Date: 2 September 1999 (02.09.99)
(21) International Application Number: PCT/US99/00637 (22) International Filing Date: 12 January 1999 (12.01.99) (30) Priority Data: 60/076,316 27 February 1998 (27.02.98) US (71) Applicant: BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. [US/US]; 900 Ridgebury Road, Ridgefield, CT 06877 (US). (72) Inventors: TATAKE, Revati, J.; 14 Misty Vale Road, Sandy Hook, CT 06482 (US). MARLIN, Steven, D.; 28 Cobblers Mill Road, Sandy Hook, CT 06482 (US). BARTON, Randall, W.; 10 Paul Spring Hollow, Farmington, CT 06031 (US). (74) Agents: RAYMOND, Robert et al.; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877 (US).		(81) Designated States: AU, BG, BR, BY, CA, CN, CZ, EE, HR, HU, ID, IL, IN, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, VN, YU, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>

(54) Title: SELF-REGULATED APOPTOSIS OF INFLAMMATORY CELLS BY GENE THERAPY



(57) Abstract

This invention relates to chimeric nucleic acids and to the therapeutic induction of apoptosis in activated inflammatory cells, or cells at a site of inflammation, by introducing into those cells the chimeric nucleic acid. The chimeric nucleic acid having at least one TNF α promoter enhancer attached to a functional copy of a TNF α promoter and further attached to at least one copy of an apoptosis-inducing gene, which is further attached to a 3'UTR. The apoptosis-inducing gene is Granzyme B. The invention also relates to methods of making and using self-regulated apoptosis chimeric nucleic acids and pharmaceutical compositions containing them for treating inflammatory diseases.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

SELF-REGULATED APOPTOSIS OF INFLAMMATORY CELLS BY GENE THERAPY

5

Technical Field of the Invention

10 The present invention relates to the fields of molecular biology and immunology. More specifically, this invention relates to the induction of apoptosis in inflammatory cells by introducing into those cells a gene which induces apoptosis (programmed cell death or non-necrotic cell death) in these cells.

15 Background of the Invention

 In many inflammatory conditions, cytokines such as IL-1 β , IL-10, GM-CSF and TNF α are excessively produced as a result of mass aggregation and accumulation of inflammatory cells (Brennan F.M. *et al.*, *British Medical Bulletin* 1995, 51/2, 368-384). Upregulation and/or dysregulation of cytokines in inflamed
20 tissue may be directly or indirectly responsible for exacerbation of chronic inflammatory diseases. For example, the most marked pathology in rheumatoid arthritis (RA) is displayed at the local site of inflammation (*i.e.*, the synovial joints). Therefore, it is likely that the cytokines produced in the synovial joints of RA patients play an important role in the disease process. Of those cytokines, IL-1 β
25 and TNF α are believed to be responsible for the devastating cartilage destruction and bone erosion which characterizes RA (Dayer J.M. *et al.*, *J. Exp. Med.*, 1985, 162, 1208-1215; Gowen M. *et al.*, *Nature*, 1983, 306, 378-380). The presence of excessive amounts of IL-1 β and TNF α in the synovial joints has been shown to accelerate development of collagen-induced arthritis in rodents (Brennan F.M., *et*

al., Clin. Expt. Immunol., 1994, 97/1, 1-3).

Apoptosis is a fundamental physiological process for embryonic development and maintenance of tissue homeostasis. (Raff, M.C. *Nature*, 1992, 356, 397; Vaux, D.L. et al.. *Cell*, 1994, 76, 777). Inconsistency in this critical
5 natural process is featured in a variety of neoplastic, neurodegenerative and autoimmune diseases (Thompson, C.B., *Science*, 1995, 267, 1456). Biochemical attributes, involving signal transduction cascade, are relatively complex and are not completely understood. A variety of stimuli including activation of specific receptors, such as TNFR1 or Fas trigger evolutionary conserved execution
10 machinery involving several signaling components, that are orchestrated to cause cellular demise (Ashkenazi, A. and Dixit, V.M., *Science*, 1998, 181, 1305).

Granzyme B is a serine protease, primarily found in cytoplasmic granules of cytotoxic T lymphocytes and natural killer cells. Granzyme B plays an important role in inducing apoptotic changes in target cells by cytotoxic cell mediated killing
15 (Huesel J.W. et al, *Cell*, 76, 977-987, 1994; Shi, L. et al.. *J. Exp. Med.* 176,1521-1529, 1992), partly by catalyzing cleavage and activation of several caspases (Salvesen, G.S. and Dixit, V.M., *Cell*, 91, 443-446, 1997) as well as by caspase independent pathways (Andrade, F. et al. *Immunity* 8,451-460,1998). Structurally, Granzyme B is produced as polypeptide containing a leader peptide separated by an
20 inactivating di-peptide (Gly-Glu) from the active Granzyme B polypeptide. Like the caspases, Granzyme B recognizes substrates specifically at aspartic acid for cleavage.

TNF α is a cytokine, mainly synthesized by monocytes, macrophages and lymphocytes in response to activation. The classic elements governing its
25 expression are located in the proximal or the distal promoter region (reviewed in Pauli, U. *Critical Rev. in Eukaryotic Gene Expression*, 1994, 4, 323-344). Summarized below are regions that have been described to play a significant role in the TNF α promoter activity:

- a) TNF α -responsive elements were shown to be located between base
30 pairs
-100 to -125. The region -108 to -101 bp contains a palindrome, TGAGCTCA, which is similar to AP-1 sequence that contains PMA-

responsive elements. Multiple copies of -125 to -85 bp confer a 7 to 11 fold induction of the expression of the reporter gene (Leitman, D. et al, J. Biol. Chem. 266, 9343, 1991).

- 5 b) PMA-responsive elements were shown to be present in between -101 to -286 base pairs (Hensel, G. et al, Lymphokine Res. 8, 347, 1989).
- c) Anti-CD3 antibody-induced (as well as Ca-ionophore- induced) responsive elements were shown to lie between -118 to -80 base pairs. The KappaB3 (GGGTTTCTCC) sequence in this region is of high importance for CsA-sensitive activation of the TNF α promoter by Ca-ionophore. These elements are suggested to be optimally functional in the context of their own promoter (Goldfield, et al.. J. Exp. Med. 178, 1356, 1993).
- 10 d) In U937 cells, the PMA responsive element is located between -95 to -36 bp and the cAMP-responsive element (CRE) is mapped to position -107 to -99 bp. This region does not respond to PMA (Economou, J.S. et al , J. Exp. Med. 170, 321, 1989).
- 15 e) All three kappaB sites [viz. kappaB1 (-587 to -577), kappaB2 (-210 to -202) and kappaB3 (-98 to -87)]bound virus-inducible protein, although deletion of these sites did not affect virus inducibility (Goldfield, A. et al, PNAS, 87, 9769, 1990). Further more, deletion mutants of kappaB sites show that they are not primary targets for PMA stimulation of human TNF α gene (Goldfield, A. et al J. Exp. Med. 174, 73, 1991).
- 20 f) In the murine system, the TNF α promoter constructs -1059, -695 and -655 bp are strongly LPS inducible. This LPS-inducibility was greatly reduced in a -451bp construct and further between -301 and -241 bp. The -1059 bp fragment of TNF α promoter was silent in macrophages and was strongly expressed after LPS stimulation. The largest drop of activation was at -695 to -655 bp, which contains a kappaB element in the murine TNF α promoter (Shakhov, A.N. et al, J. Exp. Med., 1990, 171,35; Drouet, C. et al, J. Immunol., 1991, 147, 1694).
- 25
- 30

Elements in the 3' untranslated region (3'UTR) of the TNF α gene are known to be important for post-transcriptional regulation. Analysis of the influence of 3' UTR has been made in the murine system, wherein conjunction with the homologous promoter, LPS inducibility was very strong. Using murine TNF α promoter system, it was shown that 3'UTR effectively inhibits CAT activity in three non-macrophage cell lines viz. HeLa, NIH3T3 and L929. The sequence TTATTTAT was repeated several times in the 3'UTR and was proposed to be involved in regulation (Han, J., *et al.*, *J. Immunology*, 1991, 146, 1843-1848; Crawford, F.K., *et al.*, *J. Biol. Chem.*, 1996, 271, 22383-22390).

A variety of cells such as activated macrophages, activated T cells, macrophage-like synoviocytes as well as fibroblasts-like synoviocytes, and transformed macrophage-like synoviocytes (also referred to as pannocyte) are present in the inflamed joints. An invasive structure, called the pannus, derives from the hyperplastic nature of synoviocytes and pannocytes. The pannus may result from an excessive proliferation of cells and/or diminished apoptosis in these cells. Proliferative index in these cells was shown to be relatively low. Therefore, hyperplasia in synoviocytes could be due to abnormalities in apoptosis of the synovial lining. The frequency of cells with end stage apoptosis is low in the synovium. Abnormalities of p53 mutations, which could result in resistance to apoptosis are reported in the RA synovial fibroblasts. Additionally, excessive amounts of pro-inflammatory cytokines such as TNF α and IL-1 β are produced in the synovial tissue by a variety of cell types at the cartilage-pannus junction, including cells of the macrophage lineage, macrophage-like synoviocytes, activated T-cells and possibly fibroblast-like synoviocytes (Chu C.Q. *et al.*, *Arthritis & Rheumatism*, 1991, 34, 1125-1132; Deleuran B.W., *et al.*, *Arthritis & Rheumatism*, 1992, 35, 1170-1178). This perpetuates the infiltration of inflammatory cells and production of more pro-inflammatory cytokines and factors, which are responsible for synovial cell proliferation. In addition to the above described inflammatory effects, TNF α plays a ubiquitous and key role in a variety of pro-inflammatory events.

TNF α induces IL-1 β activity in monocytes. Indeed, anti-TNF α neutralizing antibodies have been shown to reduce overall IL-1 β production

(Portillo, et al., *Immunol.*, 1989, 66, 170-175; Brennan F.M., et al., *British Medical Bulletin* 1995, 51/2, 368-384). Thus, an added benefit to blocking the effect of the inflammatory cytokine TNF α was the reduction in production of the equally destructive pro-inflammatory mediator, IL-1 β . Furthermore, it is well known that TNF α is a transcriptional activator of other inflammation-related genes. For example, the presence of TNF α stimulates production of other cytokines (such as GM-CSF) and cell surface receptors, including HLA class II antigens and adhesion molecules (Alvaro-Garcia J.M., et al., *J. Exp. Med.*, 1989, 146, 865-875), that perpetuate recruitment of activated T cells and neutrophils resulting in synovial inflammation and hyperplasia and ultimately, in augmented destruction of cartilage and bone (Allen J.B., *J. Exp. Med.*, 1990, 171, 231).

Conventional therapy against inflammatory disorders is typically directed against symptomatic inflammation. Such therapy provides only temporary relief without significantly delaying disease progression. In contrast, therapies targeting TNF α and other factors induced in the inflammatory process are likely to be more promising. For example, in collagen-induced arthritis animal models, an anti-TNF α antibody and soluble TNF α receptor-IgG chimera effectively reduced paw swelling, joint involvement and cartilage and bone destruction (Williams R.O. et al., *Proc. Natl. Acad. Sci.*, 1992, 89, 9784-9788). Human trials using both humanized anti-TNF α antibodies and TNF α receptor-IgG chimeric molecules produced dramatic results (Elliott M.J., et al., *Arthritis and Rheumatism*, 1993, 36, 1681-1690; Elliott M.J., et al., *Lancet*, 343, 1105-1110). Although treatment with these TNF α antagonists appears to be well tolerated, it also results in production of antibodies against the recombinant proteins. Thus, these therapies may not be suitable for long term treatment and do not achieve true disease abatement.

WO 97/07828 discloses methods of treating by gene therapy a patient with cellular accumulation or a chronic inflammatory disease which was a result of a defective apoptosis-regulating gene, more specifically p53. The treatment restores the defect with a wild-type gene attached to a promoter which drives the apoptosis-regulating gene expression.

In order to actually modify progression of the disease, TNF α must be continuously targeted using TNF α -specific therapies. Such a continuous therapeutic

protocol was impractical with these biologic agents and would be difficult to administer in the long term.

In an alternate therapeutic option, inflamed synovium may be removed using surgical (Herold N. and Schroder H.A., *Acta Orthop. Scand.*, 1995, 66, 252-254; Ogilvie-Harris D.J. and Weisleder L., *Arthroscopy*, 1995, 11, 91-95),
5 chemical (Cruz-Esteban C. and Wilke W.S., *Bailliere's Clinical Rheumatol.*, 1995, 9, 787-801) or radiation-induced synovectomy (Cruz-Esteban C. and Wilke W.S., *Bailliere's Clinical Rheumatol.*, 1995, 9, 787-801). Marginal to good results follow arthroscopic surgery. Non-surgical synovectomy is performed using various
10 chemical agents such as osmic acid, alkylating agents such as nitrogen mustard and thiotepa, methotrexate. Unfortunately, non-surgical synovectomies (including chemical and radiation-induced) are procedurally complicated, provide only short term relief and show only patchy reduction of the synovial hyperplasia. Furthermore, most of the non-surgical alternatives are potential teratogens.
15 Moreover, an innate inflammatory response is concomitant with tissue damage arising from the chemical or surgical intervention. Finally, it should be noted that these approaches suffer from the risks and side-effects commonly associated with conventional pharmaceutical therapy and invasive surgical procedures, including the expense and inconvenience of hospitalization and rehabilitation.
20 Accordingly, a need still exists for an effective therapeutic approach to treating inflammatory disorders in general and RA in particular.

Summary of the Invention

The invention provides methods and compositions relating to a novel
25 apoptosis induced destruction of TNF α producing cells. It was therefore an object of the invention to provide unique chimeric nucleic acid molecules having at least one TNF α promoter enhancer region (comprising the nucleic acid SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 11, SEQ ID NO: 12 or conservative substitution or allelic variants thereof) attached to a TNF α promoter, the TNF α promoter further being
30 attached to a nucleic acid sequence encoding the Granzyme B protein or conservative substitution or allelic variants thereof which in turn was further attached to a 3'UTR nucleic acid sequence.

Another objective of this invention was to provide TNFp-AIG and the like chimeric nucleic acid constructs, processes for making them, methods of using them, and preparations containing them.

It was a further object to provide a method of treating an inflammatory disorder by administering to a patient in need of such treatment a pharmaceutically effective amount of the composition having the chimeric nucleic acid molecule described herein.

It was yet a further objective of this invention to provide a method for the induction of apoptosis in cells transfected with the TNFp-AIG chimeric nucleic acid, a method for the *in vitro* selection of TNF α non-producer somatic cell variants in a population, a method for identifying dominant/negative genes responsible for the genesis of a TNF α non-producing population and a method for identifying products responsible for regulation of TNF α production .

These and other objectives will be readily appreciated by those of ordinary skill in the art based upon the following detailed disclosure of the invention.

Brief Description of the Figures

Figure 1 is a schematic representation of TNFp-AIG chimeric nucleic acids of this invention. The Apoptosis Inducing Gene (AIG) is Granzyme B.

Figure 2 is a schematic drawing depicting the results of gene therapy using a TNFp-AIG chimeric nucleic acids of this invention.

Figure 3 is a summary of deletion constructs used for identification of the inducible cis elements of the TNF α promoter using luciferase gene (Luc) expression as the reporter system.

Figure 4(a) shows results of the representative experiment performed to assess expression of luciferase gene driven by deletion constructs of the TNF α

promoter in transiently transfected Jurkat Cells. Histograms represent stimulation index as a measure of inducibility by activating agent PMA. Jurkat cells produce TNF α following stimulation with PMA.

Figure 4(b) Results of the representative experiment performed to assess
5 expression of luciferase gene driven by deletion constructs of the TNF α promoter in transiently transfected THP-1 Cells. Histograms represent stimulation index as a measure of inducibility by activating agent, LPS. THP-1 cells produce TNF α following stimulation with LPS.

10 Figure 5 is a flow chart for preparation of the TNFpGB using selected native elements of the TNF α promoter and Granzyme B.

Figure 6 (a and b) provide a summary of results from representative
experiments performed to see expression of the chimeric TNFp-Granzyme B
15 (TNFpGB). Expression of various clones of TNFpGB constructs are expressed in transiently-transfected Jurkat cells (Figure 6a) The expression of Granzyme B was assessed by Western blot analysis using anti Granzyme B antibody. Bands representing Granzyme B in transfected cells are identified by arrows. Induction of apoptosis by expression of TNFpGB chimeric nucleic acids was assessed by
20 transient transfection in Jurkat cells (Figure 6b). Apoptosis was assessed by Cell Death ELISA. In both experiments, histograms with sparse dots represent non-stimulated control, where cells were transfected with a chimeric nucleic acid shown and transfected cells were not stimulated with PMA. Solid histograms represent induction of apoptosis following stimulation with PMA, either in the control
25 transfections (transfected with -1005Luc3'UTR) or chimeric nucleic acids expressing Granzyme B.

Figure 7 (a and b) is a diagrammatic representation of a TNFp-AIG
chimeric nucleic of this invention, comprising multiple copies of the inducible cis
30 elements of the TNF α promoter which, in turn, drive expression of the AIG (Figure 7a). A diagrammatic representation of a TNFpAIG chimeric nucleic acid, comprising multiple copies of the inducible cis elements of the TNF α promoter,

driving expression of the AIG, downstream of which are 3' untranslated region of the TNF α gene (TNF3'UTR) (Figure 7b). 3'UTR of the TNF α gene was implicated in the regulation of the inducible expression of TNF α (Han, J., *et al.*, *J. Immunology*, 1991, 146, 1843-1843, Crawford, E.K., *et al.*, *J. Biol. Chem.*, 1997, 272, 21120-21137, and Figure 9).

Figure 8 (a and b) are flow charts of schemes for preparing TNF α super - promoter-Granzyme B chimeric constructs.

Figure 9 shows a summary of the results of two experiments to show the regulatory effect of the TNF3'UTR on inducible expression of the luciferase reporter gene. The transient transfection was performed in a fibroblast cell line. Dotted histograms represent inducibility of TNFpLuc in the absence of TNF3'UTR and solid histograms represent inducibility of TNFpLuc in the presence of TNF3'UTR. Similar results are obtained in the Jurkat cell.

Figure 10 is a diagrammatic representation for the selection of TNF α non-producer somatic cell variants within a TNF α -producing cell population and identification of dominant negative suppressive genes responsible for inhibiting TNF α production.

Figure 11(a) is a diagrammatic representation of the identified Enhancer Regions (ER) ER1 (SEQ ID NO: 4), ER2 (SEQ ID NO: 5), ER3 (SEQ ID NO: 11) and ER4 (SEQ ID NO: 12) of the TNF α promoter and insertion of two copies of said ER upstream of the native -120 TNF α promoter.

5 Figure 11(b) shows results of experiments performed to assess expression of luciferase gene driven by the native -120 TNF α promoter, to which two copies of enhancer regions ER1, ER2, ER3 and ER4 are attached at the 5'end. The construct driving expression of the luciferase gene were in transiently transfected Jurkat Cells. Histograms represent stimulation index as a measure of inducibility by
10 activating agent PMA. Jurkat cells produce TNF α following stimulation with PMA.

Figure 11 (c) shows results of experiments performed to assess expression of luciferase gene driven by the native -120 TNF α promoter, to which two copies of enhancer regions ER1, ER2, ER3 and ER4 are attached at the 5'end. The construct
15 driving expression of the luciferase gene were in transiently transfected THP-1 Cells. Histograms represent stimulation index as a measure of inducibility by activating agent LPS. THP-1 cells produce TNF α following stimulation with LPS.

Figure 12 is a graphical representation of the chimeric nucleic acid
20 -706TNFpGB3'UTR sequence wherein the promoter fragment sequence is denoted by lower case alphabet, the linker fragment sequence is denoted by upper case italicized alphabet, the Granzyme B fragment sequence is denoted by upper case alphabet, and the TNF α 3'UTR fragment sequence is denoted by lowercase underlined alphabet.

25

Figure 13 is a graphical representation of the chimeric nucleic acid
-1005TNFpGB3'UTR sequence wherein the promoter fragment sequence is denoted
by lower case alphabet, the linker fragment sequence is denoted by upper case
italicized alphabet, the Granzyme B fragment sequence is denoted by upper case
30 alphabet, and the TNF α 3'UTR fragment sequence is denoted by lowercase

underlined alphabet.

Detailed Description of the Invention

5 The invention described herein overcomes the drawbacks in the field by providing novel chimeric nucleic acid molecules for use in therapeutic compositions and methods of using such compositions. The compositions are directed to selectively induce apoptosis in TNF α producing cells causing destruction of these cells.

10 As used herein, the abbreviation 3'UTR means 3' untranslated region.

 The abbreviation "AIG" refers to Apoptosis Inducing Gene. An AIG includes Granzyme B.

 The abbreviation "CsA" refers to Cyclosporin A, a biologically active fungal metabolite with immunosuppressive properties.

15 The abbreviation "DN" refers to dominant/negative gene products which have negative affect on expression or function of other genes or gene products.

 The abbreviation "ER" refers to Enhancer Region, whereby ER1 has SEQ ID NO: 4, ER2 has SEQ ID NO: 5, ER3 has SEQ ID NO: 11, and ER4 has SEQ ID NO: 12.

20 The abbreviation "GB" refers to Granzyme B.

 The abbreviation "PMA" refers to Phorbol Myristate Acetate.

 The abbreviation "RA" refers to Rheumatoid Arthritis.

 The abbreviation "TNF α " refers to tumor necrosis factor alpha.

 The terms "TNF promoter", "TNF α promoter" and "TNFp" are used
25 interchangeably herein. Unless noted to the contrary, these terms refer to the entire nucleotide sequence corresponding to a native TNF α minimal promoter sequence attached to one or more upstream enhancer elements, either present naturally, native, or genetically engineered in the laboratory.

 Amino acid "substitutions" are defined as having one for one amino acid
30 replacements. They are conservative in nature when the substituted amino acid has similar structural and/or chemical properties. Examples of conservative replacements are substitution of a leucine with an isoleucine or valine, an aspartate

with a glutamate, or a threonine with a serine.

"Conservative variants" refer to the substitutions of amino acids in a polypeptide.

5 "Allelic variants" refer to the variation at the nucleic acid and protein level either due to conservative or non-conservative substitutions giving rise to alternative form of the same gene.

"Reporter" molecules are chemical moieties used for labelling a nucleic acid or amino acid sequence. They include, but are not limited to, radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents. Reporter
10 molecules associate with, establish the presence of, and may allow quantification of a particular nucleic or amino acid sequence.

"Reporter genes" are nucleic acids and fragments thereof encoding a functional protein, such as luciferase, that may be used to assess the activity of heterologous promoters.

15 A "functional fragment" of a polynucleotide or nucleic acid comprises all or any part of the nucleotide sequence having fewer nucleotides, which can be used as genetic material sufficient to initiate transcription of a gene or encode for a functional subunit of a polypeptide.

20 This invention was based upon evidence that apoptosis of inflammatory cells in certain inflammatory diseases was therapeutically beneficial. The invention specifically relates to self-regulated apoptosis by gene therapy. Broadly speaking, in the practice of the invention, a chimeric nucleic acid comprising at least one promoter enhancer attached to at least one functional copy of a minimal promoter,
25 the promoter being a gene or combination of genes activated in inflammatory cells or in cells at a site of inflammation, was attached to at least one copy of an apoptosis-inducing gene (AIG), such that the expression of the AIG was driven by the promoter, thus targeting the inflammatory cells. The promoters of inducible genes activated in inflammation include the nucleic acid sequence of the TNF α
30 promoter and conservative substitution or allelic variants thereof. Chimeric nucleic acids according to the invention comprise enhancer, promoter, and AIG elements in direct, distal, or proximal attachment, and combinations thereof. As mentioned

above and will be discussed in more detail below, in some embodiments, multiple copies of the enhancer, promoter, and/or AIG were employed for maximal efficacy.

In order that the invention herein described may be more fully understood, the following detailed description is set forth, with emphasis on chimeric nucleic acids comprising at least one TNF α promoter enhancer attached to at least one functional copy of a minimal TNF α promoter and further attached to at least one copy of an AIG for illustrative purposes only. Though the examples that follow also employ these types of constructions, it will be appreciated by skilled workers that the basic constructs described herein may be altered to provide other embodiments that utilize products, processes, methods, and compositions of the invention with other promoters comprising inducible genes activated in inflammation such as the types listed above that exhibit similar functions that can be used to target cells at the site of infection.

15

The Apoptosis-Inducing Gene (which will sometimes be referred to herein as AIG) was driven by a TNF α promoter (TNFp) or other inducible gene activated in inflammation. In one embodiment, apoptosis was selectively induced in those cells capable of producing TNF α . The TNFp-AIG or other chimeric nucleic acid may be conveniently introduced *in vivo* using conventional gene therapy techniques. Advantageously, in the embodiment wherein the chimeric nucleic acid was TNFp-AIG, it was expressed in only those cells producing the inflammatory cytokine, TNF α . In addition, since the TNFp-AIG chimeric nucleic acid contains the TNF α promoter elements, it also sequesters inducible, TNFp-selective transcription factors. Such sequestration results in a reduction in endogenous production of TNF α . The present invention relates specifically to TNFp-AIG and similar gene constructs, cells containing chimeric nucleic acids, methods for induction of apoptosis in cells transfected with chimeric nucleic acids, pharmaceutical compositions containing chimeric nucleic acids, methods for *in vitro* selection of TNF α non-producer somatic cell variants within a TNF α producing cell population and the like, a method for identifying dominant negative/dominant suppressive genes responsible for inhibiting TNF α production and therapeutic

30

methods using the chimeric nucleic acid.

To clarify the discussion below of exemplary TNFp-AIG chimeric nucleic acids of this invention, the following sequences are illustrated:

5 SEQ ID NO: 1 is the nucleotide sequence corresponding to the full-length, reference human TNF α promoter sequence, as published (Takashiba S., *et al.*, *Gene*, 1993, 131, 307-308). Nucleotide numbers used herein refer to the numbering of this sequence.

10 SEQ ID NO: 2 is the native TNF α promoter sequence of the gene that was used in this invention (-1077 nucleotides from the transcription start site, TSS). There are a few differences in the sequence of the TNFp in SEQ IDNO: 1 and SEQ ID NO:2. Such differences in the nucleotide sequences of the TNF α promoter have been reported (Takashiba S., *et al.*, *Gene*, 1993, 131, 307-308).

15 SEQ ID NO: 3 is the native minimal TNF α promoter sequence (nucleotide -120 through -TSS), which includes at least one enhancer element (k3 site); see Pauli, U., *Crit. Rev. in Eucaryotic Gene Expression*, 1994, 4, 323-344; Rhoades K.L., *et al.*, *J. Biol. Chem.*, 1992, 267, 22102-22107; and Takashiba S., *et al.*,
20 *Gene*, 131, 307-108).

 SEQ ID NO: 4 is the enhancer region 1 (ER1) of the TNF α promoter encompassing nucleotides -1005 to -905.

25 SEQ ID NO: 5 is the enhancer region 2 (ER2) of the TNF α promoter encompassing nucleotides -706 to -517.

 SEQ ID NO: 6 is additional multiple cloning sites (MCS) genetically engineered upstream of the -120 minimal TNF α promoter in the -120pGL3
30 construct.

 SEQ ID NO: 7 is the 3' untranslated region (3'UTR) of the TNF α gene

(Nedwin, G.E., *et al.*, *Nucleic Acid Research*, 1985, 13, 6361-6373).

SEQ ID NO: 8 is the full length Granzyme B.

SEQ ID NO: 9 is the truncated Granzyme B, devoid of the nucleotides
5 encoding leader peptide and inactivating di-peptide.

SEQ ID NO: 10 is the full length Granzyme B, containing the nucleotides
encoding the leader peptide, but devoid of the nucleotides encoding the inactivating
di-peptide.

SEQ ID NO: 11 is the enhancer region 3 (ER3) of the TNF α promoter
10 encompassing nucleotides -234 to -120.

SEQ ID NO: 12 is the enhancer region 4 (ER4) of the TNF α promoter
encompassing nucleotides -234 to -65.

SEQ ID NO: 13 is the chimeric nucleic acid -706TNFpGB 3'UTR.

SEQ ID NO: 14 is the chimeric nucleic acid -1005THFpGB 3'UTR.

15

The elements of the TNF α promoter for preparation of chimeric nucleic
acid constructs according to this invention were selected from elements, which
were capable of inducing expression of a therapeutic gene driven by the TNF α
promoter. These promoter elements will be referred to herein as "inducible cis
20 elements", "cis-inducible elements" or "enhancer elements" of the TNF α promoter.

The enhancer elements may be physically linked to the minimal promoter
sequence, or separated from the minimal promoter by a linker sequence which may
or may not have unique restriction sites. Thus, as summarized above, enhancer
25 elements may be attached directly, distally, proximally, or any combination thereof,
to chimeric nucleic acids of the invention. These were typically constructed
upstream of the promoter. Example TNF α enhancer elements are set out in SEQ ID
NO: 4, SEQ ID NO: 5, SEQ ID NO: 11, and SEQ ID NO: 12; functional fragments

or variants and combinations thereof may be employed. Some preferred gene constructs according to this invention include those that have multiple copies of the enhancer elements, *i.e.*, two or more copies. Some embodiments have about 2 to 25, more narrowly 2 to 10, and even more narrowly, 2 to 5 copies.

5

The terms "TNF promoter", "TNF α promoter" and "TNFp" are used interchangeably herein. Unless noted to the contrary, these terms refer to the entire nucleotide sequence corresponding to a native TNF α minimal promoter sequence attached to one or more upstream enhancer elements (either present naturally *i.e.* native, or genetically engineered in the laboratory). Examples include, but are not limited to, SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, and functional fragments, variants, and mixtures of any of these. Many functional fragments and variants of these TNF α sequences and others described herein share a sequence homology of at least about 80%, and in some cases over 90%, to their native and genetically engineered counterparts, but these are known to skilled workers and defined in the references cited herein.

This invention provides a novel therapeutic method comprising the step of introducing into the cells of a mammal a chimeric nucleic acid comprising an apoptosis-inducing gene (AIG) driven by the TNF α promoter (TNFp). Example chimeric nucleic acids of the invention are set out in SEQ ID NOs 13 and 14; functional fragments or variants of these may also be employed. Without wishing to be bound by theory, as a result of being controlled by the TNFp, AIG was expressed in only those cells producing the inflammatory cytokine, TNF α . Therefore, any cells expressing TNF α will be self-destructive, while cells that do not express TNF α will be unaffected. Advantageously, this methodology can target any TNF α -producing cells, such as activated macrophages, activated T-cells, macrophage-like, fibroblast-like synoviocytes and primary cells residing in RA joints. Indeed, the targeted TNF α -producing cell can be one which normally does or normally does not carry or expresses an apoptosis gene in its native, unaltered form. Therefore, using the chimeric nucleic acids and methods of this invention, the cellular sources of TNF α can be destroyed in a highly selective manner.

Another advantage of using the TNFp-AIG chimeric nucleic acid of this invention was that TNFp sequesters transcription factors needed by endogenous TNFp, thereby leading to a reduction in endogenous TNF α production. In one example, TNFp was present in the therapeutically targeted cell in vast excess. This
5 may be accomplished by introducing multiple copies of the transfected gene into the cell. Alternatively, the TNFp-AIG chimeric nucleic acid according to this invention can contain multiple copies of the inducible cis elements of the TNF α promoter. As mentioned above, multiple copies of the "inducible enhancer elements" of TNFp are present in some embodiments of the TNFp-AIG chimeric nucleic acids of this
10 invention. By including multiple copies of the inducible cis elements of the TNFp construct, the transcriptional factors needed by the transfected cell to produce TNF α were sequestered by the exogenously introduced sequence. This preferred chimeric TNFp-AIG construct was characterized by an increased effectiveness in competing for the TNFp-specific transcription factors as compared to chimeric nucleic acids of
15 this invention containing only a single enhancer element linked to TNFp. The "inducible super promoter" constructed in this way was capable of (1) more effectively competing for TNF α specific inducible transcription factors and (2) driving expression of the apoptosis inducing gene in an augmented fashion by virtue of multiple enhancing elements.

20 In rheumatoid arthritis patients, synovectomy, *i.e.*, removal of synovial tissue, has been shown to be clinically beneficial. Unlike conventional and surgical synovectomy procedures, the cell-targeted therapeutic method described herein targets only cells producing TNF α . Thus, advantageously, the introduction and expression of the TNFp-AIG chimeric gene and subsequent induction of apoptosis
25 do not induce an inflammatory response. Accordingly, methods of this invention were comparatively selective and result in minimal tissue damage and a reduction in inflammation.

The products and methods described herein are useful for the treatment of
30 other inflammatory disorders as well. Such inflammatory disorders include, but are not limited to, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, psoriasis, graft versus host disease, lupus erythematosus, insulin-de-

pendent diabetes mellitus, psoriatic arthritis, sarcoidosis, hypersensitivity pneumonitis, ankylosing spondylitis and related spoldyloarthropathies, Reiter's syndrome and systemic sclerosis. Thus, this invention encompasses methods for treating an inflammatory disorder in a patient administering to a patient in need of such treatment a pharmaceutically effective amount of a pharmaceutical composition having the chimeric nucleic acid according to the invention. Apoptosis was induced in inflammatory cells or cells at a site of inflammation of the patient by introducing into the cells at least one chimeric nucleic acid of the invention. This was typically accomplished by preparing a pharmaceutical composition containing at least one chimeric nucleic acid of the invention and typically a pharmaceutically acceptable carrier, and administering the composition to a patient using standard means known to those skilled in the art. The pharmaceutical composition can be delivered directly to the site of inflammation using local topical, intravenous, intraperitoneal, and similar methods. Further methodology discussed below.

15

In addition to the therapeutic indications, the chimeric nucleic acids according to this invention can be used in a variety of useful screening and selection methods. In one such method, TNF α non-producer somatic cell variants within a TNF α producing cell population can be selected in vitro by introducing a TNFp-AIG chimeric nucleic acid into the TNF α producing cell population. Cells producing TNF α will undergo apoptosis. Cells that do not produce TNF α will survive. Selection of those cell variants possessing the survival phenotype was an easy way to identify TNF α non-producer cells. Such a selection process may be used to determine expression of genes that act in-trans to regulate activity of the TNF α promoter, thereby reducing TNF α production. Such genes were characterized as dominant negative (DN) /dominant suppressive genes in other systems (Behrends S., *et al.*, *J. Biol. Chem.* 1995, 270, 21109-21113; Zhang S., *et al.*, *J. Biol. Chem.*, 1995, 270, 23934-23936; Watowich S.S., *et al.*, *Mol. Cell Biol.*, 1994, 14/6, 3535-3549).

30

In a further *in vitro* method, a TNFp-AIG chimeric nucleic acid according to this invention can be used to identify dominant negative gene responsible for the

genesis of a TNF α non-producing cell population. According to this method, a TNFp-AIG chimeric nucleic acid according to this invention was introduced into cells that produce TNF α . Barring the presence of a dominant negative gene, those cells should undergo apoptosis upon activation. Therefore, it can be deduced that surviving variants possess a dominant negative gene capable of down-regulating TNF α production. The dominant negative gene can be readily identified by producing a cDNA library and transfecting cell lines (*e.g.*, Jurkat and THP-1). These cells were either stable transfectants of an inducible TNFp-AIG chimeric nucleic acid or TNFp-luciferase gene. TNFp-AIG transfected cells will be selected for the survival phenotype following *in vitro* activation; survival phenotype was indicative of the effect of the DN genes. In the cells transfected with TNFp-luciferase gene, reduction in the luciferase activity will be indicative of the DN gene effect. Dominant negative genes identified using this protocol can be used as the future therapeutic agents themselves. Such genes will be the candidates for gene therapy in order to reduce TNF α production.

The methods utilized for gene transfer were grouped into two broad categories:

1. Direct approach : *In situ* transduction of the therapeutic gene into target cells such as synoviocytes using a suitable vector as a carrier for the therapeutic gene. The vector containing therapeutic gene was injected directly into the affected area (*e.g.*, an arthritic joint).
2. Indirect approach : *Ex-vivo* transfection of the therapeutic gene into target cells such as synoviocytes. In this approach, the synovium was removed from joints, synoviocytes were isolated and cultured *in vitro*. *In vitro* cultured cells were transfected with the therapeutic gene, and genetically modified synoviocytes were transplanted back into the synovium.

For *in vivo* transfer, several vectors have been evaluated for their efficacy in gene delivery (Nita, *et al.*, *Arthritis & Rheumatism*, 1996, 39/5, 820-828).

Among the vectors used for gene therapy, the vectors derived from retroviruses were by far the best developed. They were able to insert genetic material in the host genome and produce stable transfectants. These vectors, however were unable to infect non-dividing cells and, since they were inserted in the host genome, the possibility of insertional mutagenesis cannot be ruled out. In comparison, the vectors derived from adenoviruses infect dividing as well as non-dividing cells and deliver DNA episomally. The disadvantage of adenovirus based vectors was that these vectors continue to produce viral proteins in infected cells making them potentially antigenic. A third type of viral based vectors was derived from Herpes simplex viruses (HSV), which were also capable of infecting dividing as well as non dividing cells.

Among the non-viral vector systems, cationic liposomes and naked plasmid DNA have been evaluated. Liposomes were at the most advanced stage of development, although certain types of cells such as muscle and skin take up, retain and express naked plasmid DNA.

Particle-mediated gene-delivery system is also possible (Rakhmievich, *et al.*, *PNAS*, 1996, 93, 6291) and is a promising approach.

The following "*in vivo*" gene delivery protocols can be used to deliver the chimeric nucleic acids of this invention:

(1) Nita *et al.*, *Arthritis and Rheumatism*, 1996, 39, 820-823

In vivo experiment in rabbits:

Each vector was injected intra-articularly into one knee joint. For viral vectors, between 10^8 and 10^9 particles suspended in 0.5 ml balance salt solution were injected per knee.

Liposome-DNA complexes (200 nmoles of DC-Chol complexed with 20 μ g of DNA/ml) in 1 ml balance salt solution were injected per knee.

(2) *Methods in Molecular Medicine : Gene Therapy Protocols*, Paul Robbins, ed.,

1997, Barr *et al.*, pages 205-212

Adenovirus-based vector delivery to hepatocytes : Rat hepatocytes 1×10^{11} PFU in 100 g animal.

In dogs (12-17 kg), portal vein was perfused with about 1.5×10^{11} PFU/kg gives 1 adenovirus genome copy per diploid copy of host DNA.

In rabbits (2-4kg), 1.5×10^{13} virus particles (about 1.5×10^{11} PFU) gives 100% hepatocyte transduction; 4×10^{12} virus particles give 50-75% transduction.

Yang N-S, *et al.*, 281-296

Gold particle-mediated gene delivery : Transfection of mammalian skin tissue- 0.1, 0.5, 1.0 and 2.5 μ g of DNA/mg particle gives linear relationship with transgene expression levels.

Nabel, *et al.*, 297-305

Liposome-mediated gene delivery in humans:

Protocol 1: 15nmol DC-Chol/Dope liposomes combined with 1 μ g DNA in 0.7 ml. 0.2 ml of the above mixture was injected into the patient's melanoma nodule. For catheter delivery, 0.6 ml of the solution was delivered into the artery.

Protocol 2: 15nmol DMRIE/Dope liposomes combined with 5 μ g DNA in 1.0 ml.

For direct intra-tumor injections, DNA concentrations range from 3 μ g complexed with 4.5nM DMRIE/Dope to 300 μ g complexed with 450 nM DMRIE/Dope.

(3) Roessler, *et al.* 369-374

Gene transfer to synovium:

A range of doses, 10^9 - 10^{12} adenovirus particles containing therapeutic gene/joint were used. However, the optimal dose for any particular experimental series needs to be determined empirically, and was dependent on both the properties of the recombinant adenoviral genomic backbone being used as well as the transgene

being expressed.

For the indirect approach, a variety of methods were well established, including utilization of cationic lipid or cationic polymer-based transfection and electroporation.

Any of the above-referenced techniques can be altered to suit the particular needs of those of ordinary skill in the art. Such modifications are well within the level of skill possessed by ordinary practitioners and do not require undue experimentation. These obvious variations are within the scope of this invention.

Examples

In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustrating some preferred embodiments of this invention, and are not to be construed as limiting the scope of this invention in any way.

EXAMPLE 1

Production of TNF α -Granzyme B Constructs

In order to construct chimeric Granzyme B driven by the enhancer cis elements of the TNF promoter, either in a single or multiple copies of the same region or various regions, identification of the regions of interest responsible for optimal inducible expression of the reporter gene was performed.

Selection of the TNF α promoter elements for constructing a chimeric nucleic acid.

The regions of the TNF α promoter were amplified by polymerase chain reaction (PCR) using primers encompassing various deletion constructs of the TNF α promoter (Figure 3). The regions identified by other investigators in various other

cellular systems were used as reference (Rhoades, *et al.*, *J. Biol. Chem.*, 1992, 267, 22102-22107; Leitman, *et al.*, *Mol. Cell Biol.*, 1992, 12, 1352-1356; Pauli U., *Crit. Reviews Eukaryotic Gene Expression*, 1994, 4, 323-344). The PCR-amplified genes were then cloned upstream of a reporter gene, such as luciferase, in a commercially available promoterless vector. These constructs were tested for their constitutive and inducible expression in various cell lines such as Jurkat (T lymphoblastoid), U973 (myelomonocytic), THP-1 (monocytic), fibroblasts and in vitro cultured human synoviocytes. Identification of the regions responsible for inducible expression of the reporter gene was primarily based on the results obtained using two TNF α -producing cell lines, viz. Jurkat (following stimulation with PMA) and THP-1 (following stimulation with LPS) (Figure 4 a and b). These cells were transiently transfected by using well established methods and commercially available reagents, *e.g.*, DEAE dextran and Superfect. The cis-elements of the TNF α promoter that were responsible for inducible expression of the reporter gene were then used for constructing TNFp-Granzyme B chimeric nucleic acids.

Construction of TNFp-Granzyme B chimeric nucleic acids.

Granzyme B coding region was amplified using oligo-dT-primed cDNA as a template, which was obtained from PHA/anti-CD3 -activated human peripheral blood lymphocytes that were maintained in IL-2 containing medium. Sense primers corresponding to codons 1-7, and 21-27 were used for amplification of full length (SEQ ID NO: 8) or truncated (SEQ ID NO: 9) forms of Granzyme B. Anti-sense primer used was same in both amplifications to give products corresponding up to stop codon, i.e. residue 248. Di-peptide deleted Granzyme B constructs (SEQ ID NO: 10) were prepared using full length Granzyme B (SEQ ID NO: 8) as a template. Mutagenic sense and antisense complementary primers, flanking 15 nucleotides on either sides of, but not including, the six nucleotides corresponding to codons 19 and 20 (inactivating di-peptide) were used to create deletion. The constructs were made using QuickChange mutagenesis kit (Stratagene). Nucleic acid fragments encoding di-peptide-deleted Granzyme B were subcloned downstream of the TNF α promoter by replacing the luciferase gene in the deletion constructs -706

and -1005 of the TNF α promoters (Figure 5). The entire 3' untranslated region of the TNF α gene (SEQ ID NO: 7) was PCR-amplified and was inserted downstream of the nucleic acid fragment encoding di-peptide deleted Granzyme B gene driven by -706 and -1005 deletion fragments of the TNF α promoter. The entire sequence
5 of the chimeric nucleic acids is in SEQ ID NO:13and14.

Construction of TNF α super promoter-Granzyme B chimeric nucleic acids.

Two broad preferred regions, viz., ER1(-1005 to -905) (SEQ. ID NO:4), ER2(-706 to -517) (SEQ ID NO: 5), of the TNF α promoter, containing elements
10 responsible for inducible expression of the reporter gene described above (Figure 4a and 4b) were PCR amplified and were ligated upstream of the minimal native promoter (-120 through TSS, SEQ ID NO: 3), either as a single copy or multiple copies. Two more regions ER3(-234 to -120) (SEQ. ID NO:11), and ER4(-234 to -65) (SEQ. ID NO:12) of the TNF α promoter were also identified as enhancer
15 regions which were employed in the chimeric constructs using the strategies described below. The super promoter contains multiple (2-10) cassettes of the above mentioned regions containing inducible promoter elements (Figure 7). This was achieved by PCR amplifying the regions of interest using primers synthesized with restriction sites inserted at the 5' end of each of the primers. These unique
20 restriction sites flank the amplified gene product of interest. Preferably, PCR amplified AIG was cloned downstream of the TNF α super promoter, replacing the luciferase reporter gene in the original construct as described (Figure 5) for the native TNF α promoter.

The schemes for construction of a TNF α super promoter and the linker
25 sequences representing unique restriction sites (these restriction sites were absent in the selected elements of the TNF α promoter and Granzyme B) for efficient directional insertion was outlined below and depicted in Figure 8:

Scheme 1:

30 STEP 1: Insertion of the TNF α minimal promoter (-120 to TSS) into the pGL3 basic (promoterless) luciferase vector (Promega):

The elements of pGL3 basic vectors that were used for construction of the

chimeric nucleic acid TNFp-AIG are shown below.

_____KpnI.SacI.MluI.NheI.SmaI.XhoI.BglII.HindIII. [luciferase].XbaI _____

5 The minimal promoter was PCR amplified using primers containing XhoI and BglII.HindIII sites, so that XhoI was at the 5' end and BglII.HindIII sites were at the 3' end of the amplified product. This fragment was inserted into the polylinker of the pGL3 basic vector using these same restriction sites. This construct was referred to as "Construct A1" and was as follows:

10

____KpnI.SacI.MluI.NheISmaIXhoI.(-120 to TSS BglII).HindIII.[luciferase].XbaI _____

STEP 2: The enhancer fragment (ER1 ,ER2, ER3, or ER4) was PCR amplified using the primer containing several restriction sites. The resulting fragment will
15 have restriction sites KpnI.AatII.BssHII at the 5' end and NsiI.SpeI.MluI at the 3' end as follows:

5' KpnI.AatII.BssHII.(ER1 ,ER2, ER3, or ER4).NsiI.SpeI.MluI 3'. The fragment was inserted into the "Construct A1" generated in STEP 1 using KpnI and MluI restriction sites. This construct was referred to as "Construct B1" and was as
20 follows:

_____KpnI.AatII.BssHII.(ER1 ,ER2, ER3, or
ER4).NsiI.SpeI.MluI.NheI.SmaI.XhoI(-120 to TSS BglII).HindIII.
[luciferase].XbaI _____

25

STEP 3: The TNF α enhancer fragment (ER1 ,ER2, ER3, or ER4) was amplified using the primers containing restriction sites AatII and BssHII to generate the PCR product as follows:

5' AatII. (ER1 ,ER2, ER3, or ER4).BssHII 3'. This fragment was cloned into the
30 "Construct B1" using these same restriction sites. This construct was referred to as "Construct C1" and was as follows:

_____KpnI.AatII.(ER1 or ER2).BssHII.(ER1 ,ER2, ER3, or
ER4).NsiI.SpeI.MluI.NheI SmaI.XhoI(-120 to TSS
BglII).HindIII.[luciferase].XbaI _____

- 5 STEP 4: The TNF α enhancer fragment (ER1 ,ER2, ER3, or ER4) was amplified using the primers containing restriction sites NsiI and SpeI to generate the PCR product as follows:

5' NsiI. (ER1 ,ER2, ER3, or ER4).SpeI 3'. This fragment will be cloned into the "Construct C1" using these same restriction sites. This construct was referred to as

- 10 "Construct D1" and was as follows:

_____KpnI.AatII.(ER1, ER2, ER3 or ER4).BssHII.(ER1 ,ER2, ER3, or
ER4).NsiI. (ER1 ,ER2, ER3, or ER4).SpeI.MluI.NheI SmaI.XhoI(-120 to
TSSBglII).HindIII.[luciferase].XbaI

15

- STEP 5: Granzyme B coding regions were PCR-amplified using the primers containing BglII and XbaI restriction sites generating the fragment as follows: 5' EcoRI.BglII.[Granzyme B].XbaI 3". This fragment was inserted into the "Construct D1" using BglII and XbaI. The resulting construct was referred to as
- 20 "Construct E1" and was as follows:

_____KpnI.AatII.(ER1 ,ER2, ER3, or ER4).BssHII. (ER1 ,ER2, ER3, or
ER4).NsiI.(ER1 ,ER2, ER3, or ER4).SpeI.MluI.NheI.SmaI.XhoI(-120 to
TSS.BglII).[Granzyme B].EcoRI XbaI _____

25

Alternatively scheme 2 was followed:

Scheme 2:

- STEP 1: Same as in scheme 1 giving rise to "Construct A1", which was as follows:

30

KpnI.SacI.MluI.NheI.SmaI.XhoI.(-120 to TSS BglII).HindIII.[luciferase].XbaI

STEP 2: Insertion of additional Multiple Cloning Sites (SEQ ID NO: 6).

Two complementary oligonucleotides (5' phosphorylated) providing

_____NheI.SacII.EcorV.AflIII.AatII.AvrII.SpeI.PvuII.XhoI_____ were synthesized using commercial sources. These oligonucleotides were annealed and then
 5 cloned into NheI and XhoI sites of the "Construct A1". The resulting construct referred to as "Construct B2" and it was as follows:

_____KpnI.SacI.MluI.NheI.SacII.EcorV.AflIII.AatII.AvrII.SpeI.PvuII.XhoI.(-120 to TSS BglII).HindIII.[luciferase].XbaI_____

10

STEP 3: The TNF α enhancer fragment (ER1 ,ER2, ER3, or ER4) was amplified using the primers containing restriction sites SpeI.PvuII at the 5' end, and XhoI at the 3' end to generate the PCR product as follows: 5' SpeI.PvuII.(ER1 ,ER2, ER3, or ER4).XhoI 3'. This fragment was cloned into the "Construct B2" using SpeI and
 15 XhoI restriction sites. This construct was referred to as "Construct C2" and was as follows:

_____KpnI.SacI.MluI.NheI.SacII.EcorV.AflIII.AatII.AvrII.SpeI.PvuII. (ER1, ER2, ER3, or ER4).XhoI.(-120 to TSS BglII).HindIII.[luciferase].XbaI_____

20

STEP 4: The TNF α enhancer fragment (ER1 ,ER2, ER3, or ER4) was amplified using the primers containing restriction sites AvrII. SpeI at the 5' end, and PvuII at the 3' end to generate the PCR product as follows: 5' AvrII.SpeI.(ER1 ,ER2, ER3, or ER4).PvuII 3'. This fragment was cloned into the "Construct C2" using AvrII
 25 and PvuII restriction sites. This construct was referred to as "Construct D2" and was as follows:

_____KpnI.SacI.MluI.NheI.SacII.EcorV.AflIII.AatII.AvrII.SpeI.(ER1 ,ER2, ER3, or ER4).PvuII.(ER1 ,ER2, ER3, or ER4).XhoI.(-120 to TSS
 30 BglII).HindIII.[luciferase].XbaI_____

Thus, using this strategy at least seven copies of the enhancer regions

(ER1, ER2 ER3, or ER4 individually or in combination), one at a time, can be added by using one more restriction site upstream of the previous one in PCR amplification of the enhancer regions of choice. Once the desired number of copies of the enhancer regions were added, AIG was inserted downstream of the super
5 promoter as described in the STEP 5 of the scheme 1.

The inducible expression of the chimeric TNFp-Granzyme B gene was tested by transient transfection of the cell lines mentioned above. The expression of TNFp-Granzyme B nucleic acid was measured by detecting apoptosis of transfected cells, assessing AIG expressed proteins in Western blots using commercially
10 available antibodies and assessing protease activity using commercially available, well documented specific synthetic tetrapeptide substrate.

Regulation of the TNFp-driven expression of a reporter gene.

The 3' untranslated region of the TNF α gene plays an important role in
15 regulation of the TNF α biosynthesis. It was involved in translational expression of the TNF α gene in normal, non-activated states. Importantly, these elements allow de-repression to occur when TNF α -producing cells were activated by external stimuli (Han, J., *et al.*, *J. Immunology*, 1991, 146, 1843-1848; Crawford, F.K., *et al.*, *J. Biol. Chem.*, 1996, 271, 22383-22390).

Genetic constructs were made in which the entire 3' untranslated region
20 (SEQ ID NO: 13) was inserted downstream of the luciferase gene driven by deletion fragments, viz., -120, -706 and -1005 of the TNF α promoter. The results of the transient expression of these constructs are summarized in Figure 9. Using the strategy, 3'UTR was also inserted downstream of Granzyme B the TNFpGB
25 chimeric construct (Figures 6(a), 6(b), 12, and 13).

EXAMPLE 2

Testing Protocols

30 In Vitro Methods:

Luciferase assay: Luciferase activity was determined using commercially available

reagents (Promega).

Granzyme B gene expression:

- a) Western blots of the transfected cell lysates were developed using anti-Granzyme B antibody.
- b) Apoptosis of transfected cells: Apoptosis of transfected cells due to Granzyme B was determined by staining nuclei by propidium iodide (Krishan, A., J. Cell Biol., 66, 1994, 188-193) and by commercially available Cell Death ELISA kit (Boehringer Mannheim).

Animal Models

Rabbit model of IL-1 β -induced arthritis (Pettipher E. R., *et al.*, *Proc. Natl. Acad. Sci.*, 1986, 83, 8749-8753): IL-1 β was injected into the knee joints of New Zealand White rabbits. Intra-articular injection of IL-1 β causes dose-dependent infiltration of leukocytes into the joint space and loss of proteoglycan from the articular cartilage.

Antigen-Induced arthritis : Intra-articular injection of antigen (ovalbumin) into knee joints induces leukocyte accumulation and cartilage degradation that closely resembles rheumatoid arthritis in humans. The joint swelling following the injection was sustained for 14 days.

Scid mice-human synoviocytes model (Hourii J.M., *et al.* *Current Opinions in Rheumatol.*, 1995, 7, 201-205; Sack U., *et al.*, *J. Autoimmunity*, 1995, 9, 51-58; Geiler T., *et al.* *Arthritis & Rheumatism*, 1994, 37, 1664-1671): These were recently developed models for arthritis in which fresh synovial tissue from RA patients was implanted with normal human cartilage into scid mice either subcutaneously, under the renal capsule (Geiler T., *et al.*, *Arthritis & Rheumatism*, 1994, 37, 1664-1671), or into knee joints (Sack U., *et al.*, *J. Autoimmunity*, 1995, 9, 51-58). The implants grow with arthritis-like characteristics, including formation of pannus tissue of high cellular density, bone and cartilage erosion, development of multinuclear giant cells, and invasion of cartilage by synovial fibroblasts.

Indirect Method: Synoviocytes were transfected *in vitro* with the therapeutic gene and transplanted back in rabbits. Arthritis was induced in these rabbits by injecting IL-1 β and expression of the therapeutic gene following activation was assessed. Activation-induced expression of the chimeric nucleic acid induces apoptosis in transplanted cells.

Direct Method: Intra-articular injection of the chimeric nucleic acids. Any of the gene delivery methods described above, including naked plasmid DNA, cationic liposome-mediated delivery can be used. For use of viral vector-based delivery, chimeric nucleic acids were cloned in suitable vectors. The vectors were then modified by deleting eukaryotic promoter present in these vectors. Intra-articular injection of the therapeutic genes inserted in appropriate vectors can then be done to assess therapeutic as well as prophylactic efficacy.

EXAMPLE 3

Selection of TNF α Non-Producer Somatic Cell Variants

Cells (THP-1, Jurkat) were stably transfected *in vitro* with TNFp-AIG chimeric nucleic acid. After several cycles of stimulation, which induces apoptosis in the cells expressing the TNFp-AIG gene, surviving cells were then collected. A cDNA library from these cells was constructed, which was used for functional cloning (Legerski R and Peterson C., *Nature*, 1992, 359, 70-73; Jaattela M., *et al.*, *Oncogene*, 1995, 10, 2297-2305).

EXAMPLE 4

Identification and Characterization of Dominant Negative (DN) Genes

THP-1 and Jurkat cells stably transfected with TNFp-AIG were subjected to repeated cycles of stimulation to activate expression of TNFp-AIG. The cells, which do not express negative regulatory genes, undergo apoptosis, whereas those expressing dominant negative genes survive. In these surviving cells DN gene

products act in-trans with the TNF α promoter, thereby inhibiting its activations to transcribe AIG, ultimately resulting in survival phenotype. cDNA library was constructed using polyadenylated mRNA from these cells. The DN genes which rescue TNFp-AIG-transfected THP-1 or Jurkat cells from apoptosis were identified
5 by functional cloning as described for other genes (Legerski R. and Peterson C., *Nature*, 1992, 359, 70-73; Jaattela M., *et al.*, *Oncogene*, 1995, 10, 2297-2305).

The above description was for the purpose of teaching the person of ordinary skill in the art how to practice the present invention, and it was not
10 intended to detail all those obvious modifications and variations of it which will become apparent to the skilled worker upon reading the description. It was intended, however, that all such obvious modifications and variations be included within the scope of the present invention, which was defined by the following claims. The claims are intended to cover the claimed components and steps in any sequence
15 which was effective to meet the objectives there intended, unless the context specifically indicates the contrary.

The papers cited herein are expressly incorporated in their entireties by reference.

WHAT IS CLAIMED IS:

1. A chimeric nucleic acid molecule comprising:
at least one TNF α promoter enhancer region attached to a TNF α promoter, the enhancer region comprising the nucleic acid SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 11, SEQ ID NO: 12 or conservative substitution or allelic variants thereof;
the TNF α promoter further being attached to a nucleic acid sequence encoding the Granzyme B protein or conservative substitution or allelic variants thereof which in turn is further attached to a 3'UTR nucleic acid sequence.
2. The chimeric nucleic acid molecule according to claim 1 wherein there is present two to five TNF α promoter enhancer regions, and wherein any of the enhancer regions comprise SEQ ID NO: 5, SEQ ID NO: 12 or combinations thereof.
3. The chimeric nucleic acid molecule according to claim 2 wherein the TNF α promoter comprises the nucleic acid SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or conservative substitution or allelic variants thereof.
4. The chimeric nucleic acid molecule according to claim 1 wherein the nucleic acid molecule sequence is selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14 and conservative substitution or allelic variants thereof.
5. The chimeric nucleic acid molecule according to claim 1 wherein the 3'UTR is ligated downstream of the Granzyme B nucleic acid sequence.
6. A pharmaceutical composition comprising a chimeric nucleic acid molecule according to claim 1.
7. A method of treating an inflammatory disorder comprising administering to a patient in need of such treatment a pharmaceutically effective amount of the

composition according to claim 6.

- 8 The method according to claim 7 wherein the inflammatory disorder is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, Guillain-Barre syndrome, Crohn's disease, ulcerative colitis, psoriasis, graft versus host disease, lupus erythematosus, insulin-dependent diabetes mellitus, psoriatic arthritis, sarcoidosis, hypersensitivity pneumonitis, ankylosing spondylitis, Reiter's syndrome, and systemic sclerosis.
9. The method according to claim 8 wherein the inflammatory disorder is rheumatoid arthritis.
10. A process for constructing a chimeric nucleic acid molecule comprising at least one TNF α promoter enhancer attached to a functional copy of a minimal TNF α promoter attached to at least one copy of a functional apoptosis-inducing nucleic acid molecule which is further attached to a TNF α -3'UTR nucleic acid sequence, wherein the expression of the apoptosis-inducing nucleic acid is driven by the TNF α promoter comprising the steps of:
 - (a) amplifying a nucleic acid molecule comprising a TNF α promoter by a polymerase chain reaction using primers encompassing deletion constructs of the TNF α promoter;
 - (b) cloning the PCR-amplified nucleic acid obtained in step (a) upstream of a reporter nucleic acid sequence to produce a construct;
 - (c) testing the constructs obtained in step (b) for their constitutive and inducible expression in at least one TNF α -producing cell line;
 - (d) selecting the TNF α promoter responsible for inducible expression of the reporter in the cell line;
 - (e) PCR-amplifying TNF α promoter regions that enhance expression of the reporter to obtain an enhancer and ligating at least one copy of the enhancer upstream of the promoter;
 - (f) inserting at least one copy of a apoptosis-inducing nucleic acid

molecule downstream of the TNF α promoter by replacing the reporter with the apoptosis-inducing nucleic acid deletion constructs; and,

(g) PCR-amplifying a TNF α -3'UTR and ligating downstream of the apoptosis-inducing nucleic acid molecule to obtain the chimeric nucleic acid molecule.

11. The process according to claim 10 wherein two or more copies of the enhancer are inserted upstream of the promoter.
12. The process according to claim 10 wherein reporter nucleic acid sequence is luciferase.
13. The process according to claim 10 wherein the enhancer comprises a sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 11 and SEQ ID NO: 12.
14. The process according to claim 13 wherein the apoptosis-inducing nucleic acid is Granzyme B or conservative substitution or allelic variants thereof.
15. The process according to claim 10 producing a chimeric nucleic acid molecule selected from the group consisting of SEQ ID NO: 13, SEQ ID NO: 14, and conservative substitution or allelic variants thereof.
16. The process according to claim 10 wherein the cell lines for testing constructs are selected from the group consisting of T lymphoblastoid, myelomonocytic, monocytic, fibroblast, cultured human synoviocytes and primary cells residing in RA.
17. A process for screening dominant negative genes comprising:
transfecting a non-producing TNF α cell population with a sequence comprising the chimeric nucleic acid molecule according to claim 1;
stimulating expression of the inserted sequence; and

selecting surviving cells possessing dominant negative genes.

18. The process according to claim 17 wherein the sequence comprises the chimeric nucleic acid molecule according to claim 2.





Fig. 1








Fig. 3

**Fig. 4a**

**Fig. 4b**

pGL3 basic vector elements




Fig. 5




Fig. 6a




Fig. 6b




Fig. 7B




Fig. 7A




Fig. 8a




Fig. 8b




Fig. 9




Fig. 10





Fig. 11a




Fig. 11b




Fig. 11c

Chimeric Nucleic Acid (-706TNFpGB3'UTR)

CTCGAGTccttggagccaagactgaaaccagcattatgagtctccgggtcagaatgaaagaagaa
 ggctgccccagtggggtctgtgaattcccggggtgatttcactccccggggtgtcccaggtt
 gtccctgctacccccacccagcctttcctgaggctcaagcctgccaccaagccccagctccttct
 ccccgaggggacccaaacacaggcctcaggactcaacacagcttttccctccaaccccggttttctc
 tcctcaaggactcagctttctgaagccctccagttctagttctatcttttctgcatectgt
 ctggaagttagaaggaaacagaccacagacctgggtcccaaaaagaaatggaggcaataggttttga
 ggggcatggggacgggttcagcctccagggtcctacacacaaatcagtcagtgggccagaagacc
 cccctcggaatcgagcagggaggatggggagtgtgaggggtatccttgatgcttgtgtgtcccca
 actttccaaatccccgcccccgcatggagaagaaaccgagacagaaggtgcagggccactaccg
 cttcctccagatgagctcatgggtttctccaccaaggaagtttccgctgggttgatgattctttc
 ccgcccctcctctcgccccagggacatataaaggcagttgttggcacaccagccagcagacgctc
 cctcagcAGATCTATGCAACCAATCCTGCTTCTGCTGGCCTTCCTCCTGCTGCCAGGGCAGATGC
 AATCATCGGGGGACATGAGGCCAAGCCCCACTCCCGCCCCTACATGGCTTATCTTATGATCTGGGA
 TCAGAAGTCTCTGAAGAGGTGCGGTGGCTTCCTGATACAAGACGACTTCGTGCTGACAGCTGCTCA
 CTGTTGGGGAAGCTCCATAAATGTCACCTTGGGGGCCACAATATCAAAGAACAGGAGCCGACCCA
 GCAGTTTATCCCTGTGAAAAGACCCATCCCCATCCAGCCTATAATCCTAAGAACTTCTCCAACGA
 CATCATGCTACTGCAGCTGGAGAGAAAGGCCAAGCGGACCAGAGCTGTGCAGCCCCCTCAGGCTACC
 TAGCAACAAGGCCAGGTGAAGCCAGGGCAGACATGCAGTGTGGCCGGCTGGGGGCAGACGGCCCC
 CCTGGGAAAACACTCACACACACTACAAGAGGTGAAGATGACAGTGCAGGAAGATCGAAAGTGC GA
 ATCTGACTTACGCCATTATTACGACAGTACCATTGAGTTGTGCGTGGGGGACCCAGAGATTAAAAA
 GACTTCCTTTAAGGGGGACTCTGGAGGCCCTCTTGTGTGTAAACAAGGTGGCCAGGGGATTGTCTC
 CTATGGACGAAACAATGGCATGCCTCCACGAGCCTGCACCAAAGTCTCAAGCTTTGTACACTGGAT
 AAAGAAAACCATGAAACGCTACTAAGAATTCTCTAGaggaggacgaacatccaaccttcccaaacg
cctccccctgccccaatccctttattacccccctccttcagacaccctcaacctcttctgggtcaaaa
agagaattgggggcttagggtcggaacccaagccttagaactttaagcaacaagaccaccacttcga
aacctgggattcaggaatgtgtggcctgcacagtgaagtgcctggcaaccactaagaattcaaactg
gggcctccagaactcactggggcctacagctttgatccctgacatctggaatctggagaccagggg
gcctttggttctgcccagaatgctgcaggacttgagaagacctcacctagaaattgacacaagtgg
accttaggccttcctctctccagatgtttccagacttccttgagacacggagcccagccctccca
tggagccagctccctctatttatgtttgcacttgtgattatttattatttatttatttattt
tttacagatgaatgtatttatttgggagaccggggtatcctgggggacccaatgtaggagctgcct
tggctcagacatgttttccgtgaaaacggagctgaacaataggctgttcccatgtagccccctggc
ctctgtgccttcttttgattatgttttttaaaatatttatctgattaagttgtctaacaatgctg
atttggtgaccaactgtcactcattgctgagcctctgctccccaggggagttgtgtctgtaatcgc
cctactattcagtgccgagaTCTAGA

Figure 12

Promoter sequence-lowercase, linker sequence-uppercase Italics,
 Granzyme B sequence-uppercase, TNFα3'UTR sequence -lowercase
 underlined

Promoter sequence-lowercase, linker sequence-uppercase *Italics*, Granzyme B sequence-uppercase, TNF α 3'UTR sequence -lowercase underlined

SEQUENCE LISTING

□

□

<110> Tatake, Revati J.

□

Marlin, Steven D

□

Barton, Randall W

□

□

<120> Self-Regulated Apoptosis of Inflammatory Cells by Gene

□

Therapy

□

□

<130> 9/137

□

□

<140>

□

<141>

□

□

<150> 60/076,316

□

<151> 1998-02-27

□

□

<160> 14

□

□

<170> PatentIn Ver. 2.0

□

□

<210> 1

□

<211> 1178

□

<212> DNA

□

<213> Human

□

□

<220>

□

<223> Human TNF-alpha promoter

□

□

<400> 1

□
ggggaagcaa aggagaagct gagaagatga aggaaaagtc agggctctgga ggggcggggg 60
□
tcaggagct cctgggagat atggccacat gtagcggctc tgaggaatgg gttacaggag 120
□
acctctgggg agatgtgacc acagcaatgg gtaggagaat gtccagggtc atggaagtcg 180
□
agtatcgggg acccccctt aacgaagaca gggccatgta gagggcccca gggagtga 240
□
gagcctccag gacctccagg tatggaatac aggggacgtt taagaagata tggccacaca 300
□
ctggggccct gagaagtga agcttcatga aaaaaatcag ggacccaga gttccttgga 360
□
agccaagact gaaaccagca ttatgagtct ccgggtcaga atgaaagaag aaggcctgcc 420
□
ccagtgtgtc gtgaattccc ggggtgatt tcaactcccc ggctgtcca ggcttgtccc 480
□
tgctaccccc acccagcctt tcctgaggcc tcaagctgcc accaagcccc cagctccttc 540
□
tccccgaga ccacaacaca ggctcagga ctcaacacag cttttccctc caaccgcgtt 600
□
ttctctccct caaggactca gctttctgaa gccctccca gttctagttc tatctttttc 660
□
ctgcatcctg tctggaagtt agaaggaaac agaccacaga cctgggtccc aaaagaaatg 720
□
gaggcaatag gttttgagg gcatggggac ggggttcagc ctccagggtc ctacacacaa 780
□
atcagtcagt gggccagaag acccccctcg gaatcggagc agggaggatg gggagtgtga 840
□
gggtatcct tgatgcttgt gtgtcccaa ctttccaaat nccgcccc gcgatggaga 900
□
agaaaccgag acagaaggtg cagggccac taccgttcc tccagatgag cttatgggtt 960
□
tctccacaa ggaagttttc cgctggtga atgattctt cccgcccctc ctctcgcccc 1020
□
agggacatat aaaggcagtt gttggcacac ccagccagca gacgtccct cagcaaggac 1080
□
agcagaggac cagctaagag ggagagaagc aactgcagac ccccctgaa aacaaccctc 1140
□
agacgccaca tcccctgaca agctgccagg caggttct 1178
□

□

<210> 2

□

<211> 1096

□

<212> DNA

□

<213> Human

□

□

<220>

□

<223> Human TNF-alpha promoter

□

□

<400> 2

gagggccgcca gactgctgca ggggaagcaa aggagaagct gagaagatga aggaaaagtc 60
agggtctgga ggggcggggg tcagggagct cctgggagat atggccacat gtagcggctc 120
tgaggaatgg gttacaggag acctctgggg agatgtgacc acagcaatgg gtaggagaat 180
gtccagggct atggaagtcg agtatgggga cccccctta acgaagacag ggccatgtag 240
aggggccccag ggagtgaaag agcctccagg acctccaggt atggaataca ggggacgttt 300
aagaagatat ggccacacac tggggccctg agaagtgaga gcttcatgaa aaaaatcagg 360
gaccccagag ttccttgga gccaagactg aaaccagcat tatgagtctc cgggtcagaa 420
tgaaagaaga aggcctgccc cagtgggggtc tgtgaattcc cgggggtgat ttcactcccc 480
ggggctgtcc caggcttgct cctgctaccc ccaccagcc tttcctgagg cctcaagcct 540
gccaccaagc cccagctcc ttctccccgc agggacccaa acacaggcct caggactcaa 600
cacagctttt ccctccaacc ccgttttctc tcctcaagg actcagcttt ctgaagcccc 660
tcccagttct agttctatct tttcctgca tcctgtctgg aagttagaag gaaacagacc 720
acagacctgg tccccaaaag aaatggaggc aataggtttt gaggggcatg gggacgggg 780
tcagcctcca gggtcctaca cacaaatcag tcagtggccc agaagacccc cctcggaatc 840
ggagcagggg ggatggggag tgtgaggggt atccttgatg cttgtgtgtc cccaactttc 900
caaatccccg cccccgcat ggagaagaaa ccgagacaga aggtgcaggg ccactaccg 960
cttctccag atgagctcat gggtttctcc accaaggaag ttttccgctg gttgaatgat 1020
tctttccccg ccctcctctc gccccaggga catataaagg cagttgttgg cacaccagc 1080
cagcagacgc tccctc 1096

□

<210> 3

□

<211> 139

□

<212> DNA

□

<213> Human

□

□

<220>

□

<223> native minimal TNF-alpha promoter

□

□

<400> 3

□

ccgcttctctc cagatgagct catgggtttc tccaccaagg aagttttccg ctggttgaat 60
□
gattctttcc ccgccctcct ctgccccag ggacatataa aggcagttgt atggcacacc 120
□
cgccagcaga cgctccctc 139
□

□
<210> 4
□
<211> 123
□
<212> DNA
□
<213> Human
□

□
<220>
□
<223> TNF-alpha promoter enhancer region 1 (ER1)
□

□
<400> 4
□
ggggcggggg tcaggagct cctgggagat atggccacat gtagcggctc tgaggaatgg 60
□
gttacaggag acctctgggg agatgtgacc acagcaatgg gtaggagaat gtccagggtc 120
□
atg 123
□

□
<210> 5
□
<211> 190
□
<212> DNA
□
<213> Human
□

□
<220>
□
<223> TNF-alpha promoter enhancer region 2 (ER2)
□

□
<400> 5
□
tccttgaag ccaagactga aaccagcatt atgagtctcc gggtcagaat gaaagaagaa 60
□
ggcctgcccc agtggggtct gtgaattccc gggggtgatt tcaactccccg gggctgtccc 120
□
aggcttgctc ctgctacccc caccagcct ttctgaggc ctcaagcctg ccaccaagcc 180
□
cccagctcct 190
□

□
<210> 6

□
<211> 223

□
<212> DNA

□
<213> Human
□

□
<220>

□
<223> multiple cloning sites genetically engineered

□
upstream of the minimal TNF-alpha promoter in the
□
-120pGL3 construct
□

□
<400> 6

□
ggtaccgagc tcttacgcgt gctagccgcg gatatcttaa gacgtcctag gactagtcag 60
□
ctgctcgagc cgcttcctcc agatgagctc atgggtttct ccaccaagga agttttccgc 120
□
tggttgaatg attctttccc cgccctcctc tcgccccagg gacatataaa ggcagttgtt 180
□
ggcacaccca gccagcagac gctccctcag cagatctaag ctt 223
□

□
<210> 7

□
<211> 787

□
<212> DNA

□
<213> Human
□

□
<220>

□
<223> TNF-alpha untranslated region
□

□
<400> 7

□
tctagaggag gacgaacatc caaccttccc aaacgcctcc cctgccccaa tccctttatt 60
□
accccctcct tcagacaccc tcaacctctt ctgggtcaaa aagagaattg ggggcttagg 120
□
gtcggaaacc aagcttagaa ctttaagcaa caagaccacc acttcgaaac ctgggattca 180
□
ggaatgtgtg gcctgcacag tgaagtgtg gcaaccacta agaattcaaa ctggggcctc 240
□

cagaactcac tggggcctac agctttgatc cctgacatct ggaatctgga gaccagggag 300
□
cctttggttc tggccagaat gctgcaggac ttgagaagac ctcacctaga aattgacaca 360
□
agtggacctt aggccttctt ctctccagat gtttccagac ttccttgaga cacggagccc 420
□
agccctcccc atggagccag ctccctctat ttatgtttgc acttgtgatt atttattatt 480
□
tatttattat ttatttattt acagatgaat gtatttattt gggagaccgg ggtatcctgg 540
□
gggacccaat gtaggagctg ccttggtctc gacatgtttt ccgtgaaaac ggagctgaac 600
□
aataggctgt tcccatgtag ccccttgccc tctgtgcctt cttttgatta tgttttttaa 660
□
aatatttatc tgattaagtt gtctaaacaa tgctgatttg gtgaccaact gtcactcatt 720
□
gctgagcctc tgctccccag gggagtgtgt tctgtaatcg ccctactatt cagtggcgag 780
□
atctaga 787
□

□
<210> 8
□
<211> 839
□
<212> DNA
□
<213> Human
□

□
<220>
□
<223> full length Granzyme B
□

□
<400> 8
□
atgcaaccaa tctgtcttct gctggccttc ctctgtctgc ccagggcaga tgcaggggag 60
□
atcatcgagg gacatgaggg caagccccac tccgcccctt acatggctta tcttatgatc 120
□
tgggatcaga agtctctgaa gaggtgcggt ggcttctga tacaagacga cttcgtgctg 180
□
acagctgctc actgttgggg aagctccata aatgtcacct tgggggcca caatatcaag 240
□
gaacaggagc cgaccagca gtttatccct gtgaaaagag ccatcccca tccagcctat 300
□
aatcctaaga acttctcaa tgacatcatg ctactgcagc tggagagaaa ggccaagcgg 360
□
accagagctg tgcagcccct caggctacct agcaacaagg ccaggtgaa gccagggcag 420
□
acatgcagtg tggccggctg ggggcagacg gccccctgg gaaaacactc acacacacta 480
□
caagagtgga agatgacagt gcaggaagat cgaaagtgcg aatctgactt acgccattat 540
□
tacgacagta ccattgagtt gtgcgtgggg gaccagaga ttaaaaagac ttcctttaag 600
□

ggggactctg gaggccctct tgtgtgtaac aaggtggccc agggcattgt ctctatgga 660
cgaacaatg gcatgcctcc acgagcctgc accaaagtct caagctttgt aactggata 720
aagaaaacca tgaaacgcta ctaactacag gaagcaaact aagccccgc tgtaatgaaa 780
caccttctct ggagccaagt ccagatttac actgggagag gtgccagcaa ctgaataaa 839

<210> 9
<211> 782
<212> DNA
<213> Human

<220>
<223> truncated Granzyme B (devoid of the leader peptide
and inactivating di-peptide)

<400> 9
atgatcatcg ggggacatga ggccaagccc cactcccgcc cctacatggc ttatcttatg 60
atctgggatc agaagtctct gaagagggtgc ggtggcttcc tgatacaaga cgacttcgtg 120
ctgacagctg ctactgttg gggaagctcc ataaatgtca ccttgggggc ccacaatatc 180
aaggaacagg agccgaccca gcagtttatc cctgtgaaaa gagccatccc ccatccagcc 240
tataatccta agaacttctc caatgacatc atgctactgc agctggagag aaaggccaag 300
cggaccagag ctgtgcagcc cctcaggcta cctagcaaca agggccaggt gaagccaggg 360
cagacatgca gtgtggccgg ctgggggcag acggccccc tgggaaaaca ctcacacaca 420
ctacaagagg tgaagatgac agtgcaggaa gatcgaaagt gcgaatctga cttacgccat 480
tattacgaca gtaccattga gttgtgcgtg ggggaccag agattaaaaa gacttccttt 540
aagggggact ctggaggccc tcttgtgtgt aacaaggtgg ccagggcat tgtctcctat 600
ggacgaaaca atggcatgcc tccacgagcc tgcacaaaag tctcaagctt tgtacactgg 660
ataaagaaaa ccatgaaacg ctactaacta caggaagcaa actaagcccc cgctgtaatg 720
aaacaccttc tctggagcca agtccagatt tacactggga gaggtgccag caactgaata 780
aa
782

<210> 10

□

<211> 833

□

<212> DNA

□

<213> Human

□

□

<220>

□

<223> inactivating di-peptide deleted Granzyme B

□

□

<400> 10

□

atgcaaccaa tcctgcttct gctggccttc ctctgctgc ccagggcaga tgcaatcatc 60

□

gggggacatg aggccaagcc ccaactccgc ccctacatgg cttatcttat gatctgggat 120

□

cagaagtctc tgaagaggtg cgggtggcttc ctgatacaag acgacttcgt gctgacagct 180

□

gctcactgtt ggggaagctc cataaatgtc accttggggg cccacaatat caaggaacag 240

□

gagccgaccc agcagtttat ccctgtgaaa agagccatcc cccatccagc ctataatcct 300

□

aagaacttct ccaatgacat catgctactg cagctggaga gaaaggccaa gcggaccaga 360

□

gctgtgcagc ccctcaggct acctagcaac aaggcccagg tgaagccagg gcagacatgc 420

□

agtgtggccg gctgggggca gacggccccc ctgggaaaac actcacacac actacaagag 480

□

gtgaagatga cagtgcagga agatcgaaag tgccaatctg acttacgcca ttattacgac 540

□

agtaccattg agttgtgctg gggggaccca gagattaaaa agacttcctt taagggggac 600

□

tctggaggcc ctcttgtgtg taacaaggtg gccagggca ttgtctccta tggacgaaac 660

□

aatggcatgc ctccacgagc ctgcacaaa gtctcaagct ttgtacactg gataaagaaa 720

□

accatgaaac gctactaact acaggaagca aactaagccc ccgctgtaat gaaacacctt 780

□

ctctggagcc aagtccagat ttacactggg agaggtgcc a gcaactgaat aaa 833

□

□

<210> 11

□

<211> 114

□

<212> DNA

□

<213> Human

□

□

<220>

□

<223> enhancer region 3: -234 to -120 TNF-alpha promoter

□

□

<400> 11

□

gcaggaggga tggggagtgt gaggggtatc cttgatgctt gtgtgtcccc aactttccaa 60

□

atccccgccc ccgcgatgga gaagaaaccg agacagaagg tgcagggcc acta 114

□

□

<210> 12

□

<211> 169

□

<212> DNA

□

<213> Human

□

□

<220>

□

<223> enhancer region 4: -234 to -65 TNF-alpha promoter

□

□

<400> 12

□

gcaggaggga tggggagtgt gaggggtatc cttgatgctt gtgtgtcccc aactttccaa 60

□

atccccgccc ccgcgatgga gaagaaaccg agacagaagg tgcagggcc actaccgctt 120

□

cctccagatg agtcatggg tttctccacc aaggaagttt tccgctggt 169

□

□

<210> 13

□

<211> 2270

□

<212> DNA

□

<213> Human

□

□

<220>

□

<223> chimeric gene : -706TNFpGB3'UTR

□

□

<400> 13

□

ctcgagtcct tggaagccaa gactgaaacc agcattatga gtctccgggt cagaatgaaa 60

□

gaagaaggcc tgccccagtg gggctctgtga attcccggg gtgatttcac tccccggggc 120

□

tgtcccaggc ttgtccctgc tacccccacc cagcctttcc tgaggetcaa gcctgccacc 180
□
aagccccag ctctttctcc ccgcaggac ccaaacacag gcctcaggac tcaacacagc 240
□
ttttccctcc aaccccggtt tctctccctc aaggactcag ctttctgaag cccctcccag 300
□
ttctagttct atctttttcc tgcactctgt ctggaagtta gaaggaaaca gaccacagac 360
□
ctggtcccca aaagaaatgg aggcaatagg ttttgagggg catggggacg gggttcagcc 420
□
tccaggggtcc tacacacaaa tcagtcagtgc gccagaaga cccccctcgg aatcggagca 480
□
gggaggatgg ggagtgtgag gggatatcctt gatgcttgtg tgtccccaac tttccaaatc 540
□
cccgcccccg cgatggagaa gaaaccgaga cagaaggtgc agggccact accgcttcct 600
□
ccagatgagc tcatgggttt ctccaccaag gaagttttcc gctgggtgaa tgattctttc 660
□
cccgccctcc tctcgcccca gggacatata aaggcagttg ttggcacacc cagccagcag 720
□
acgtccctc agcagatcta tgcaaccaat cctgcttctg ctggccttcc tctgtctgcc 780
□
cagggcagat gcaatcatcg ggggacatga ggccaagccc cactcccgcc cctacatggc 840
□
ttatcttatg atctgggatc agaagtctct gaagaggtgc ggtggcttcc tgatacaaga 900
□
cgacttcgtg ctgacagctg ctactgttg gggaaagctcc ataaatgtca ccttgggggc 960
□
ccacaatatc aaagaacagg agccgaccca gcagtttacc cctgtgaaaa gacccatccc 1020
□
ccatccagcc tataatccta agaacttctc caacgacatc atgtactgac agctggagag 1080
□
aaaggccaag cggaccagag ctgtgcagcc cctcaggcta cctagcaaca agggccaggt 1140
□
gaagccaggg cagacatgca gtgtggccgg ctgggggcag acggccccc tgggaaaaa 1200
□
ctcacacaca ctacaagagg tgaagatgac agtgcaggaa gatcgaaagt gcgaatctga 1260
□
cttacgccat tattacgaca gtaccattga gttgtgcgtg ggggacccag agattaaaaa 1320
□
gacttccttt aagggggact ctggaggccc tcttgtgtgt aacaagggtg cccagggcat 1380
□
tgtctcttat ggacgaaaca atggcatgcc tccacgagcc tgcaccaaag tctcaagctt 1440
□
tgtactactg ataaagaaaa ccatgaaacg ctactaagaa ttctctagag gaggacgaac 1500
□
atccaacctt cccaaacgcc tcccctgcc caatcccttt attaccccct ccttcagaca 1560
□
ccctcaacct cttctggctc aaaaagagaa ttgggggctt agggtcggaa cccaagctta 1620
□
gaactttaag caacaagacc accacttoga aacctgggat tcaggaatgt gtggcctgca 1680
□
cagtgaagtg ctggcaacca ctaagaattc aaactggggc ctccagaact cactggggcc 1740
□
tacagctttg atccctgaca tctggaatct ggagaccagg gagcctttgg ttctggccag 1800
□
aatgctgcag gacttgagaa gacctcacct agaaattgac acaagtggac cttaggcctt 1860
□
cctctctcca gatgtttcca gacttccttg agacacggag ccagccctc cccatggagc 1920
□

cagctccctc tatttatgtt tgcacttgtg attatattatt atttatttat tatttattta 1980
□
tttacagatg aatgtattta tttgggagac cggggatatcc tgggggaccc aatgtaggag 2040
□
ctgccttggc tcagacatgt tttccgtgaa aacggagctg aacaataggc tgttcccatg 2100
□
tagccccctg gcctctgtgc cttcttttga ttatgttttt taaaatatatt atctgattaa 2160
□
gttgtctaaa caatgctgat ttggtgacca actgtcactc attgctgagc ctctgctccc 2220
□
caggggagtt gtgtctgtaa tcgccctact attcagtggc gagatctaga 2270
□

□

<210> 14

□

<211> 2570

□

<212> DNA

□

<213> Human

□

□

<220>

□

<223> chimeric gene : -1005TNFpGB3'UTR

□

□

<400> 14

□

ctcgagggcg ggggtcaggg agctcctggg agatatggcc acatgtagcg gctctgagga 60
□
atggggttaca ggagacctct ggggagatgt gaccacagca atgggtagga gaatgtccag 120
□
ggctatggaa gtcgagtatg gggaccccc cttaacgaag acagggccat gtagagggcc 180
□
ccagggagtg aaagagcctc caggacctcc aggtatggaa tacaggggac gtttaagaag 240
□
atatggccac aactgggggc cctgagaagt gagagcttca tgaaaaaat cagggacccc 300
□
agagttcctt ggaagccaag actgaaacca gcattatgag tctccgggtc agaataaag 360
□
aagaaggcct gccccagtgg ggtctgtgaa ttcccggggg tgatttcact ccccggggct 420
□
gtcccaggct tgtccctgct acccccaccc agcctttcct gaggcctcaa gcctgccacc 480
□
aagccccag ctctttctcc ccgcagggac ccaaacacag gcctcaggac tcaacacagc 540
□
ttttccctcc aaccccgttt tctctccctc aaggactcag ctttctgaag cccctcccag 600
□
ttctagttct atctttttcc tgcattcctgt ctggaagtta gaaggaaaca gaccacagac 660
□
ctgggtcccca aaagaaatgg aggcaatagg ttttgagggg catggggacg ggggttcagcc 720
□
tccagggctc tacacacaaa tcagtcagtg gccagaaga cccccctcgg aatcggagca 780
□
gggaggatgg ggagtgtgag gggatccctt gatgcttgtg tgtccccaac ttccaaatc 840
□

cccccccg cgatggagaa gaaaccgaga cagaagggtgc agggcccact accgcttcct 900
□
ccagatgagc tcatgggttt ctccaccaag gaagttttcc gctggttgaa tgattctttc 960
□
ccccccctcc tctcgcccca gggacatata aaggcagttg ttggcacacc cagccagcag 1020
□
acgtcccttc agcagatcta tgcaaccaat cctgcttctg ctggccttcc tctgtctgcc 1080
□
cagggcagat gcaatcatcg ggggacatga ggccaagccc cactcccgcc cctacatggc 1140
□
ttatcttatg atctgggatc agaagtctct gaagagggtgc ggtggcttcc tgatacaaga 1200
□
cgacttcgtg ctgacagctg ctactgttg gggaagctcc ataaatgtca ccttgggggc 1260
□
ccacaatatc aaagaacagg agccgaccca gcagtttata cctgtgaaaa gacccatccc 1320
□
ccatccagcc tataatccta agaacttctc caacgacatc atgctactgc agctggagag 1380
□
aaaggccaag cggaccagag ctgtgcagcc cctcaggcta cctagcaaca agggccaggt 1440
□
gaagccaggg cagacatgca gtgtggccgg ctgggggagc agggccccc tgggaaaaca 1500
□
ctcacacaca ctacaagagg tgaagatgac agtgcaggaa gatcgaaagt gcgaatctga 1560
□
cttacgccat tattacgaca gtaccattga gttgtgcgtg ggggaccag agattaaaaa 1620
□
gacttccttt aagggggact ctggaggccc tcttgtgtgt aacaagggtg cccagggcat 1680
□
tgtctcctat ggacgaaaca atggcatgcc tccacgagcc tgcaccaaag tctcaagctt 1740
□
tgtacactgg ataaagaaaa ccatgaaacg ctactaagaa ttctctagag gaggacgaac 1800
□
atccaacctt cccaaacgcc tcccctgccc caatcccttt attaccccct ccttcagaca 1860
□
ccctcaacct cttctggctc aaaaagagaa ttgggggctt agggtcggaa cccaagctta 1920
□
gaactttaag caacaagacc accacttcga aacctgggat tcaggaatgt gtggcctgca 1980
□
cagtgaagtg ctggcaacca ctaagaattc aaactggggc ctccagaact cactggggcc 2040
□
tacagctttg atccctgaca tctggaatct ggagaccagg gagcctttgg ttctggccag 2100
□
aatgctgcag gacttgagaa gacctcacct agaaattgac acaagtggac cttaggcctt 2160
□
cctctctcca gatgtttcca gacttccttg agacacggag cccagccctc cccatggagc 2220
□
cagctccctc tatttatgtt tgcacttggt attatttatt atttatttat tatttattta 2280
□
tttacagatg aatgtattta tttgggagac cgggggatcc tgggggaccc aatgtaggag 2340
□
ctgccttggc tcagacatgt tttccgtgaa aacggagctg aacaataggc tgttcccatg 2400
□
tagccccctg gcctctgtgc cttcttttga ttatgttttt taaaatattt atctgattaa 2460
□
gttgtctaaa caatgctgat ttggtgacca actgtcactc attgctgagc ctctgctccc 2520
□
caggggagtt gtgtctgtaa tcgccctact attcagtggc gagatctaga 2570
□
□

INTERNATIONAL SEARCH REPORT

Interr. Application No

PCT/US 99/00637

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/85 C12N9/64 C12Q1/68 A61K31/70 A61K48/00 //C12N5/10		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C12Q A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 98 37901 A (BOEHRINGER INGELHEIM PHARMA ;MARLIN STEVEN D (US); TATAKE REVATI J) 3 September 1998 see the whole document	1-18
X	WO 97 07828 A (UNIV CALIFORNIA) 6 March 1997 cited in the application see abstract see page 1 - page 7 see claims 1-34	1-16
X	JP 01 137976 A (ASAHI CHEM IND CO LTD) 30 May 1989 see figure 5	1-5
Y		17, 18
-/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 25 May 1999		Date of mailing of the international search report 04/06/1999
Name and mailing addresses of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Galli, I

INTERNATIONAL SEARCH REPORT

Interr. 1st Application No
PCT/US 99/00637

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 10630 A (RYCUS AVIGAIL ;KIMCHI ADI (IL); YEDA RES & DEV (IL)) 20 April 1995 see abstract see page 1, line 1 - page 5, line 23	17,18
A	WO 94 01139 A (BAYLOR COLLEGE MEDICINE) 20 January 1994 see abstract see page 1 - page 4 see example 11 see claims 1-42	1-18
A	HEUSEL J W: "CYTOTOXIC LYMPHOCYTES REQUIRE GRANZYME B FOR THE RAPID INDUCTION OF DNA FRAGMENTATION AND APOPTOSIS IN ALLOGENEIC TARGET CELLS" CELL, vol. 76, no. 6, 25 March 1994, pages 977-987, XP000676424 cited in the application see the whole document	1-18
A	CHINNAIYAN A M ET AL: "CYTOTOXIC T-CELL-DERIVED GRANZYME B ACTIVATES THE APOPTOTIC PROTEASE ICE-LAP3" CURRENT BIOLOGY, vol. 6, no. 7, 1 July 1996, pages 897-899, XP000614645 see the whole document	1-18
A	ANDERSON G P: "Resolution of chronic inflammation by therapeutic induction of apoptosis" TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 17, no. 12, 1 December 1996, page 438-442 XP004063291 see the whole document	1-18
A	TAKASHIBA S. ET AL.: "Cloning and characterization of the human TNF alpha promoter region." GENE, vol. 131, 1993, pages 307-308, XP002103473 see the whole document	1-18
A	RHOADES K. ET AL.: "The regulation of the human Tumor Necrosis Factor alpha promoter region in macrophage, T cell and B cell lines." J. BIOL. CHEM., vol. 267, no. 31, 5 November 1992, pages 22102-22107, XP002103474 see the whole document	1-18

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/00637

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 7-9
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/00637

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9837901 A	03-09-1998	AU 6672498 A	18-09-1998
WO 9707828 A	06-03-1997	AU 7018496 A	19-03-1997
		EP 0861092 A	02-09-1998
JP 01137976 A	30-05-1989	NONE	
WO 9510630 A	20-04-1995	CA 2174136 A	20-04-1995
		EP 0804613 A	05-11-1997
		JP 9505992 T	17-06-1997
WO 9401139 A	20-01-1994	AU 684050 B	04-12-1997
		AU 4670993 A	31-01-1994
		CA 2139948 A	20-01-1994
		EP 0653943 A	24-05-1995
		JP 7508988 T	05-10-1995
		US 5792751 A	11-08-1998
		US 5770580 A	23-06-1998